Nycomed Amersham Imaging taps CEO
Anglo-Norwegian pharmaceutical company Nycomed Amersham of Buckinghamshire, U.K., has tapped John Padfield as CEO of its Nycomed Amersham Imaging contrast division. Padfield joins the company from U.K. pharmaceutical firm Chiroscience Group and
Anglo-Norwegian pharmaceutical company Nycomed Amersham of Buckinghamshire, U.K., has tapped John Padfield as CEO of its Nycomed Amersham Imaging contrast division. Padfield joins the company from U.K. pharmaceutical firm Chiroscience Group and will succeed Guy Marlow as chief of Nycomed Amershams global contrast business. Marlow is retiring later this year.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
